Edwards Lifesciences Receives FDA Approval for Tricuspid Valve Repair System
Edwards Lifesciences has secured US FDA approval for its tricuspid valve repair system, marking a significant milestone for its structural heart disease portfolio.
Stocks · News reference
BTIG Reiterates Buy on Edwards Lifesciences, Maintains $110 Price Target
BTIG analyst Marie Thibault reiterates Edwards Lifesciences (NYSE:EW) with a Buy and maintains $110 price target.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
FDA Flags High-Risk Heart Device Recall At Edwards Lifesciences After Patient Death
Edwards Lifesciences recalls Commander M delivery systems following balloon burst reports and 1 death. Read the FDA alert.
Reported Earlier, Edwards Lifesciences Tells Customers To Remove Four Lots Of Commander M Delivery Systems For SAPIEN M3; FDA Flags Potentially High-Risk Issue
https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/early-alert-transcatheter-mitral-valve-delivery-system-issue-edwards-lifesciences
Barclays Initiates Coverage On Edwards Lifesciences with Overweight Rating, Announces Price Target of $110
Barclays analyst Christopher Pasquale initiates coverage on Edwards Lifesciences (NYSE:EW) with a Overweight rating and announces Price Target of $110.